GlassScriptPhysician profile
Shauna L Ruoff
NPI 1942740527
$1,291.27
in general payments reported to CMS, 2019-2025
32 companies · $742 in 2025
The $742 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $550 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.27 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.59 | 2024-2025 | |
| Sobi, INC | $124.97 | 2024 | |
| Cardiva Medical, INC. | $117.04 | 2025 | Optowire, Cardiva Vascade Mvp Vvcs 6-12f, Savvywire |
| Daiichi Sankyo INC. | $103.87 | 2024-2025 | Injectafer, Enhertu, Datroway |
| Incyte Corporation | $95.00 | 2024 | |
| Janssen Biotech, INC. | $80.69 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Celgene Corporation | $59.41 | 2024-2025 | Reblozyl |
| Janssen Pharmaceuticals, INC | $40.17 | 2024 | Xarelto |
| Tersera Therapeutics LLC | $39.07 | 2025 | Zoladex, Xermelo |
| Gilead Sciences, INC. | $35.26 | 2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $24.33 | 2025 | Keytruda |
| Beigene USA, INC. | $24.18 | 2024 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $23.82 | 2025 | |
| Fennec Pharmaceuticals, INC. | $23.64 | 2025 | Fyarro |
| Geron Corporation | $23.22 | 2025 | Rytelo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.91 | 2024 | Verzenio, Jaypirca, Retevmo |
| Pharmacosmos Therapeutics INC. | $22.90 | 2024 | Cosela |
| Novartis Pharmaceuticals Corporation | $22.27 | 2025 | |
| Genentech USA, INC. | $21.36 | 2025 | Polivy |
| Agios Pharmaceuticals, INC. | $21.04 | 2024 | Pyrukynd |
| Astrazeneca Pharmaceuticals LP | $20.69 | 2024 | Calquence |
| Sumitomo Pharma America, INC. | $20.56 | 2025 | Orgovyx |
| Beone Medicines USA, INC. | $19.14 | 2025 | Tevimbra |
| Genmab U.S., INC. | $18.93 | 2025 | Tivdak |
| Glaxosmithkline, LLC. | $18.60 | 2024 | Ojjaara, Jemperli, Zejula |
| Jazz Pharmaceuticals INC. | $16.90 | 2025 | |
| Genzyme Corporation | $16.63 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.98 | 2025 | Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $14.94 | 2025 | |
| Springworks Therapeutics, INC. | $14.89 | 2025 | Ogsiveo |
| Exelixis INC. | $14.79 | 2025 | Cabometyx |
| Abbvie INC. | $14.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shauna Ruoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.